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Simple Summary: Dendritic cells have a central role in starting and regulating immune functions in
anticancer responses. The crosstalk of dendritic cells with tumors and other immune cell subsets is
partly mediated by extracellular vesicles (EVs) secreted by both cell types and is multidirectional.
In the case of dendritic cell EVs, the presence of stimulatory molecules and their ability to promote
tumor antigen-specific responses, have raised interest in their uses as therapeutics vehicles. In this
review, we highlight how dendritic cell- and tumor cell-derived EVs affect antitumor immune
responses. In addition, we discuss the different approaches that exploit dendritic cell EVs as a novel
platform for immunotherapies and therapeutic and prophylactic anticancer vaccines.
Abstract: Extracellular vesicles (EVs) play a crucial role in intercellular communication as vehicles for
the transport of membrane and cytosolic proteins, lipids, and nucleic acids including different RNAs.
Dendritic cells (DCs)-derived EVs (DEVs), albeit variably, express major histocompatibility complex
(MHC)-peptide complexes and co-stimulatory molecules on their surface that enable the interaction
with other immune cells such as CD8+ T cells, and other ligands that stimulate natural killer (NK) cells,
thereby instructing tumor rejection, and counteracting immune-suppressive tumor microenvironment.
Malignant cells oppose this effect by secreting EVs bearing a variety of molecules that block DCs
function. For instance, tumor-derived EVs (TDEVs) can impair myeloid cell differentiation resulting
in myeloid-derived suppressor cells (MDSCs) generation. Hence, the unique composition of EVs
makes them suitable candidates for the development of new cancer treatment approaches including
prophylactic vaccine targeting oncogenic pathogens, cancer vaccines, and cancer immunotherapeutics.
We offer a perspective from both cell sides, DCs, and tumor cells, on how EVs regulate the antitumor
immune response, and how this translates into promising therapeutic options by reviewing the latest
advancement in DEV-based cancer therapeutics.
Keywords: extracellular vesicles (EVs); dendritic cell (DC); cancer; immunotherapy; vaccines;
tumor-derived EVs; oncopathogens
1. Introduction
Cancer is a very heterogeneous disease that can develop in almost any tissue due to the tumorigenic
transformation of normal cells. Malignant cell transformation is a multi-step, diverse process that
might be instigated by genetic factors. Hanahan and Weinberg outlined the six core “hallmarks of
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cancer” which are: sustained proliferative signaling, evasion of growth suppressors, activation
of invasion and metastasis, replicative immortality, angiogenesis, and resistance to cell death;
with two emerging hallmarks: metabolic deregulation and immune evasion; and two enabling
characteristics that facilitate the process: genome instability and mutation, and tumor-promotion of
inflammation [1]. These hallmarks place the spotlight on the role of the tumor microenvironment in
malignant cell progression.
Cancer thrives after escaping control checkpoints. The immune system exerts one of the main
defense mechanisms against malignant cells via immune surveillance and specific antitumor immune
responses. This comprises two arms: innate immune cells that define a first rapid line of defense and
adaptive immune cells, which drive an antigen-specific response that includes the development of
long-term memory. However, memory traits have also been observed in the innate compartment
based on epigenetic and metabolic reprogramming of cells, the so-called “trained immunity” [2].
Among innate immune cells, the main players are phagocytic cells such as neutrophils, monocytes,
and macrophages; professional antigen presenting cells (APCs) such as dendritic cells (DCs), or cell
slayers such as natural killers (NKs). Adaptive immune cells include antibody (Ab)-producers B
lymphocytes; CD8+ cytotoxic T cells; or helper cells, which include the family of CD4+ T cells (Th1, Th2,
Th17, Treg, and others). Around and within tumor environment, innate and adaptive immune cells are
crucial players [3].
Immature DCs switch to an activated state through a maturation process after stimulation by a
danger signal, such as sensing a pathogen-derived molecule, or tissue damage [4]. These cells infiltrate
the tumor and recruit effector cells. DCs represent the most effective APCs able to prime naïve T cells
and induce an effective antigen-specific antitumor defense. They include a vast variety of cellular
types with diverse functions depending on their origin, location, and properties. For instance, DCs can
be subdivided into: (i) conventional DCs (cDCs), either resident of lymphoid tissues or migratory,
where we can find cDC1 required more for pathogen/tumor immune responses or cDC2 more focus on
major histocompatibility complex (MHC)-II based responses; (ii) plasmacytoid DCs, main producers
of type 1 interferon (IFN), (iii) tissue-specific DCs such as Langerhans cells (LCs) or dermal DCs
(dDCs) and (iv) monocytic-derived DCs (moDCs), producers of tumor necrosis factor (TNF)-α and
inducible nitric oxide synthase (iNOS) [5]. In particular, cDC1 are critical in tumor surveillance,
antitumor antigen-specific T cell responses, responsiveness to immunotherapies, and are associated
with increased patient survival [6].
Extracellular vesicles (EVs) are secreted by cells to the extracellular milieu [7] and comprise mainly
three subgroups depending on their origin: (i) shedding vesicles, generated by evagination of the
plasma membrane; (ii) exosomes, generated at the multivesicular bodies and secreted by its fusion
with the plasma membrane; and (iii) apoptotic vesicles [8–10]. These vesicles are constituted by a
lipid bilayer containing an assortment of proteins, lipids, metabolites, and nucleic acids, the latter
including microRNA (miRNA), mRNA, long non-coding RNA (lncRNA), DNA and mitochondrial
DNA (mitDNA) [10–13]. Although their biogenesis is still under study, there is evidence of an
active sorting process of molecules into these vesicles as its cargo is not a mere reflection of
the cell content [10,14,15]. For instance, sorting mechanisms include tetraspanins, lipids, specific
proteins, post-translational modifications, or endosomal sorting complexes required for transport
(ESCRT)-dependent processes [14,16–19]. Their functions include a variety of cellular processes,
but these vesicles are specialized in intercellular communication [20,21]. EVs can function as autocrine,
paracrine, or endocrine entering into circulation. Once they reach their final destination, the mechanisms
underlying their internalization and signaling processes remain still under consideration [7,8,10].
Almost any type of cell can secrete EVs, including malignant cells and immune cells [8,10,11,21].
There are specific markers for each type of vesicle, specific for a certain cell type or even to
distinguish between types of vesicles from the same cell type [21–24]. Besides, EVs can be detected
in any type of biological fluid [21,22]. For example, as EVs from malignant cells convey tumor
molecules, they represent good tumor biomarkers and excellent liquid tumor biopsies [25,26].
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Interestingly, in cancer patients, the amount of serum-EVs were shown to correlate with a poor
prognosis [27]. Vesicle secretion and size heterogeneity has made it difficult to decipher their precise
origin and functions, generating some controversy [28–32].
In this review, we will highlight the intercellular communication through EVs between tumor cells
and immune cells, especially DCs. DCs actively produce EVs to enhance and modulate the immune
response, while tumor cells also secrete EVs in order to counteract this process. These characteristics
make EVs a very promising tool for the development of immunotherapies. Hence, we will also discuss
the latest advancements in vaccination and immunotherapies strategies based on EVs to stop or slow
down tumor progression and metastasis.
2. The Role of EVs in Cancer Development
2.1. Modulation of Antitumor Immunity by Dendritic Cells (DCs)-Derived Extracellular Vesicles (EVs)
2.1.1. DCs-Derived EVs (DEVs)
Immune cells can secrete immunologically active EVs [8]. One of the first studies of vesicles
in immune responses described the role of B cell-EVs carrying MHC-II molecules on their surface
in driving T cell proliferation [33]. Since then, the number of publications on immune cell-derived
vesicles functions has not ceased to grow due to their potential in human immunotherapies, for instance
against cancer. Among innate immune cells, we will focus our attention on EVs derived from DCs
(DEVs) [34]. At the end of the 90s, Zitvogel and colleagues showed that DEVs convey tumor-associated
antigens (TAAs) promoting antitumor immunity by effector T cells [35]. In particular, DEVs contain
a specific repertoire of molecules like T cell co-stimulatory molecules (CD86, CD80, CD40) [36,37],
antigen presenting molecules (MHC-II, MHC-I) [36–38], adhesion molecules (Integrins, intercellular
adhesion molecule 1 (ICAM-1), dendritic cell-specific intercellular adhesion molecule-3-Grabbing
non-integrin (DC-SIGN)) [39], NK modulation molecules (TNF-α, interleukin 15 receptor α (IL-15Rα),
NKG2D-L) [40,41] and the EV markers such as tetraspanins (CD9, CD81, CD63), ESCRT complex
proteins (Tumor susceptibility gene 101 (TSG101), ALG-2-interacting protein X (ALIX)), heat shock
proteins (HSC73, HSP84) and others (SYNTENIN-1, ACTIN) [37]. The amount of MHC molecules
or co-stimulatory molecules depends on the physiological state of the DC [38,42,43]. In fact, EVs
secreted from DCs can transfer functional MHC-I-peptide complexes to other DCs [44]. Not only
DEVs induce stimulation of naïve CD4+ T cells, but also these EVs are also used by mature DCs as
a source of tumor antigens [43,45]. Apart from proteins, nucleic acids sorted within DEVs play an
important role in the regulation of immune responses, in particular miRNAs both from immature and
mature DCs [46–48]. The secretion of these vesicles by DCs can be altered upon exposure to different
stimuli [49,50]. Highlighting the heterogeneous nature of these vesicles, different subtypes of DEVs
could also be found, each of which could perform a variety of functions [50,51].
2.1.2. DEVs Function
One of the main functions of DEVs is T cell activation (Figure 1A). EVs from an antigen-loaded
DC bearing tumor antigens that may promote CD4+ and CD8+ T cell responses by direct antigen
presentation, which leads to tumor growth suppression [35,36,52] with increased efficiency in the
case of mature DC-derived EVs [39]. DEVs can also be internalized by other DCs as a source of
exogenous peptide-loaded MHC (pMHC), which may be subsequently presented to naïve, primed,
or memory T cells [43–45,53–55]. This process has a special relevance in organ transplantation as
acceptor DCs incorporate donor-DEVs to stimulate allospecific T cells [56]. Moreover, by coating DCs
with the pMHC-loaded EVs, a process known as MHC cross-dressing, T cell response is reinforced
and amplified [57,58]. In addition, DCs can incorporate pMHC-loaded vesicles from other cell origins,
such as epithelial cells, to potentiate antigen presentation to T cells [59]. Also contributing to the global
immune response, activated T cells can recruit pMHC-loaded EVs on a leukocyte function-associated
Cancers 2020, 12, 3558 4 of 23
antigen-1 (LFA-1)-dependent manner during antigen-specific immune synapse (IS) formation [38,60],
where activated B cells also secrete a portion of these EVs [61]. Another mechanism and source of tumor
antigens is the internalization of EVs containing the full antigen or peptide, that would be presented
later by endogenous MHC-I molecules at the acceptor cell in a process called cross-presentation [62].
In fact, EVs loaded with the whole antigen are more efficient in antigen presentation than EVs bearing
only pMHC [63,64]. These antigen-loaded EVs elicit a Th1 CD4+ and CD8+ T cell response dependent
on B cell activation [65,66]. This response might also be enhanced by the presence of CD80 and
ICAM-1 in those EVs [39]. Besides, bystander T cells can promote DC maturation in the absence of
innate stimuli [67–69], which is also reflected in DEVs supporting subsequent specific antigen T cell
activation [70].
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Antigen-loaded DEVs can play many other functions in addition to modulating T cell
responses, such as promoting humoral immunity [71,72]. DEVs also contain NKG2D-L and IL-15Rα,
contributing to NK cell activation and proliferation [41]. DEVs can directly activate NK cells via
TNF-α as they display it on their surface together with FasL and TRAIL. These NK cell responses,
along with the apoptotic signaling, contribute to tumor cell removal [73]. Furthermore, EVs from
heat shocked-activated DCs bear BAT3, the ligand for NKp30, mediating cytokine release and NK cell
cytotoxicity [74] (Figure 1A). Therefore, DEVs entail an important tool to elicit the immune response
against malignant cells. These vesicles can boost both T cell and NK responses, whose cytotoxicity
leads to tumor cell killing [34,40]. Other DCs can internalize or be coated with DEVs enhancing the
antitumor response [43,58].
2.1.3. Influence of the Adaptive Response
On the other side of an antigen-specific IS, T cells can also produce EVs (TEVs) [11]. In fact,
during IS, TEVs can transfer miRNA to APCs [75,76] as B lymphocytes, thus affecting germinal center
reaction and Ab production [77]. In addition, during the IS, TEVs bearing DNA and mitDNA can
prime DCs against subsequent viral infections [78]. Furthermore, regulatory T cells (Treg), which are a
T cell subtype that maintains self-tolerance and restrains other immune responses, can also affect DC
function. EVs from Treg cells modify DC function by miRNA transfer, inducing a tolerogenic phenotype
accompanied by increased interleukin (IL)-10 and decreased IL-6 secretion [79]. Macrophage-mediated
immune suppression is also regulated by EVs from antigen-specific CD8+ T suppressor cells (Ts)
through the induction of Treg and inhibition of T cell effector proliferation [80]. Therefore, EVs at the
tumor microenvironment are crucial to delineate the final outcome of the disease, leading either to a
pro-tumorigenic or antitumorigenic situation through immunomodulation.
2.2. Modulation of the Immune Response by Tumor-Derived EVs
2.2.1. Tumor-Derived EVs (TDEVs)
Immune evasion is one of the emerging hallmarks for cancer [1]. Tumor cells manage to
escape immune responses, particularly inhibiting T cell activation and DC differentiation [81].
Notably, tumor cells can shed a large amount of EVs, highlighting the importance of vesicle
secretion during tumor development [82,83]. Tumor-derived EVs (TDEVs) can mediate many
aspects of the immune response [84]. TDEVs can alter the microenvironment of the tumor
promoting both pro/anti-inflammatory responses on monocytes, macrophages, and DCs, as well as
anti-inflammatory responses acting on NKs and Treg, thus modulating angiogenesis, invasion, apoptosis,
and metastasis [84,85]. TDEVs not only contain the typical exosomal markers, like tetraspanins
(CD81, CD63), ESCRT proteins (TSG101), heat shock proteins (HSC70), but also tumor-specific
markers such as TAAs (Her2/Neu, Mart1, TRP, GP100), MHC molecules, TNF, Fas Ligand, CD73 or
Galectin-9 [82,86]. One of the mechanisms of immune cell evasion is the expression of the programmed
death-ligand 1 (PD-L1) on the malignant cell surface. This ligand binds the receptor programmed cell
death protein (PD)-1 on CD8+ T cells, thereby inhibiting their effector functions and leading to so-called
adaptive immune resistance [87]. Interestingly, PD-L1 is also present in TDEVs suppressing CD8+
cytotoxicity and facilitating tumor growth. The number of PD-L1 vesicles increases with interferon
(IFN)-γ stimulation [88].
2.2.2. TDEVs Function on Myeloid Cells
TDEVs convey several molecules to modulate the activity of the surrounding myeloid cells.
For instance, myeloid-derived suppressor cells (MDSCs), which comprise a heterogeneous population
of immature myeloid cells with T suppressive abilities, are accumulated around the tumor through
the effect of TDEVs on bone marrow cells [89,90]. EVs can affect monocytic cell function, which is
Toll-Like Receptor (TLR)-dependent, by triggering a signaling cascade that activates the nuclear factor
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κB (NFκB) and signal transducer and activator of transcription 3 (STAT3). This signal triggers the
production of the pro-inflammatory cytokines IL-6, IL-1β, IL-8 and TNF-α [91]. NFκB renders an
important function in malignant tumor cells as it does not only play a part in immunity but also
regulates cell proliferation, apoptosis, and cell migration [92]. Furthermore, TDEVs from chronic
lymphocytic leukemia (CLL) bear a small non-coding RNA (hY4). The hY4 RNA apparently binds
to TLR7, inducing PD-L1 expression and the release of various cytokines by monocytes, such as C-C
motif chemokine ligand (CCL) 2, CCL4, and IL-6. This leads to a pro-tumorigenic phenotype favoring
the progression of the tumor [93]. Like monocytes, TDEVs loaded with small RNAs (miR-21 and
miR-29a) promote an inflammatory response via TLRs-NFκB driven by macrophages, and promote
tumor growth and metastasis [94]. Additionally, macrophages can produce inflammatory cytokines,
including IL-6, IL-8, IL-1β, CCL2, TNF-α and granulocyte colony-stimulating factor (G-CSF), also via
NFκB and TLR-dependent by TDEVs stimulation in breast [95] and gastric cancer [96]; the later with
increasing tumor cell growth, migration and invasion [96]. Furthermore, M2-polarization, which is
more pro-tumorigenic, can be controlled by EVs derived from hepatocellular carcinoma (HCC) cells
through SALL4/miRNA146a axis [97]. These TDEVs also contain lncRNA TUC339 contributing to
M1/M2-polarization of macrophages [98].
2.2.3. TDEVs Function on DCs
“Normal” DCs pose a great threat to the progression of the tumor [99]. Therefore, it is not surprising
that tumor cells contain a repertoire of mechanisms to inhibit their function, including TDEVs [100]
(Figure 1B). For instance, it has been described that TDEVs from melanoma or colorectal carcinoma
cells impair CD14+ human monocyte differentiation into DCs, leading to MDSCs generation creating
an immunotolerant environment. This process was accompanied by suppressive activity on T cell
proliferation and the release of higher amounts of IL-6, TNF-α, and transforming growth factor
(TGF)-β [101]. In another study, EVs from mammary tumor cells target CD11b+ myeloid precursors
in the bone marrow, also inhibiting their differentiation into DCs, where IL-6 plays a key role in this
blockade [89]. These effects on DCs differentiation blockade have also been observed in other types of
tumors, like renal carcinoma, Lewis lung carcinoma (LLC) or breast cancer [102,103]. For instance,
TDEVs from lung and breast cancer also block the differentiation of DCs precursor cells, inducing cell
apoptosis and leading to a drastic decrease of Th1 T cell differentiation. This effect could be partially
reverted, blocking PD-L1 [102]. Likewise, EVs released by renal carcinoma stem cells CD105+,
which express the non-classical human leukocyte antigen (HLA)-G, interfered with DCs ability to
maturate and differentiate from monocytes, counteracting their ability to stimulate T cells [103].
These TDEVs are able to modify the tumor microenvironment by inducing angiogenesis and travelling
to other organs, such as lungs, inducing the formation of a pre-metastatic niche [104]. HLA-G, -E and
-F overexpression constitutes an immunosuppressive mechanism, as it hampers the cytolytic activity of
effector cells, thus allowing malignant cells to escape immunosurveillance [105]. Specially, HLA-G has
been shown to influence DCs to behave as regulatory DCs inducing tolerance [106] and play a key role in
cancer and immune evasion [107]. Moreover, EVs secreted from melanoma cells also bear HLA-G [108].
Recently, it has been described that tumor microenvironment, including TDEVs, educate DCs to
promote tumorigenesis and metastasis. TDEVs carry heat-shock proteins such as HSP72 and HSP105
on their surface, which bind TLRs in DCs and lead to IL-6 secretion, which in turn promotes tumor
metastasis via matrix metalloproteinase (MMP) 9 [109]. Similar to monocytes, miRNAs in TDEVs also
affect DCs function. Treatment with TDEVs from pancreatic cancer cells bearing miR-203 downregulate
TLR4 and downstream cytokines (TNF-α and IL-12) in DCs [110]. In contrast, TDEVs bearing TAAs
might support immune responses against the tumor by increasing tumor antigen-presentation and T
cell response [111]. TDEVs convey miR-155 that can promote DC maturation thereby resulting in the
activation of CD8 cell antitumor response [112,113]. However, immunosuppression seems to be the
dominant effect of TDEVs over antigen cross-presentation, at least in prostate cancer [114]. Interestingly,
TDEVs from irradiated breast cancer cells transfer tumor double-stranded DNA to DCs and stimulate
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IFN type I activation via stimulator of interferon genes (STING) [115]. Hence, TDEVs contain
a repertoire of proteins, DNA and miRNAs that alter DC function and differentiation, and lead
to a change in the immune response, thus favoring or hampering tumor progression. Therefore,
the design of DC-based immunotherapies must take into account the conundrum that DC per se
might fight the tumor, but TDEVs at the tumor microenvironment might sway DCs function into a
pro-tumor phenotype.
2.2.4. TDEVs Function on Other Immune Cells
As well as innate responses, adaptive immune cells fight against malignant cancer cells.
Thus, tumor cells and TDEVs actively counteract those cells’ functions. For instance, vesicles from
pancreatic ductal adenocarcinoma (PDAC) carry TAAs that induce B cell production of auto-Abs acting
as decoys for complement-mediated cytotoxicity, originally directed towards malignant cells [116].
Besides, TDEVs decoy function can control NK cell cytotoxicity as they carry NKG2D ligands on
their surface [117,118]. As we have mentioned, DCs are specialized in T cell activation leading to an
adaptive immune response against the malignant cells. Therefore, any effect by TDEVs on DCs affects
T cell function. Nevertheless, TDEVs can also directly affect T cell function. For instance, TDEVs from
Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) carry Galectin-9 and induce T
cell anergy and death through its binding to the receptor TIM3 [119].
Tumors have managed to contain a repertoire of mechanisms to evade any antitumoral response.
In particular, the importance of TDEVs on these processes is remarkable. TDEVs can hinder many
aspects of antitumor immune response, from increasing suppressor cell populations, like MDSCs,
to decreasing antigen presentation processes. On the contrary, DCs can take advantage of TDEVs
as they convey TAAs, which might serve as a source for direct or indirect presentation mechanisms.
However, this remains to be fully characterized, especially in the case of direct TAAs presentation
carried by DEVs. Finally, diversity in EVs methodology and dendritic cell sources used in these studies
may pose a confounding factor when interpreting these data.
3. DEV-Based Cancer Therapeutics
The fine modulation of the immune responses that EVs are able to perform, as well as their
abilities for shuttling different biomolecules, including proteins that may serve as antigens to mount
an immune response, have made EVs interesting candidates for different uses in therapeutic and
prevention contexts where the immune system has a major role. Given the importance of EVs derived
from immune cells in immune modulation, and specifically of DCs as major coordinators of immune
responses, studies using DEVs pioneered the field of the application of EVs with a therapeutic purpose
and have expanded from the field of cancer [120,121] to vaccines for infectious diseases [122] and other
immune-mediated conditions affecting the nervous system [123–126].
A pioneering study using autologous DEVs showed rejection of tumors in mice when loaded
with tumor peptides and therefore used as a cell-free vaccine [35]. Driven by these observations,
several in vivo and clinical trials have followed and explored the use of EVs (more prominently DEVs)
as potential immunotherapeutic agents in cancer (reviewed in [120,121]). These therapeutic agents
possess several advantages over DC-based vaccines. First, the molecular composition of DEVs is more
restricted and controllable than that of whole cells, owing to specific sorting and loading mechanisms.
Also, DCs shelf life is more limited compared to DEVs. Regarding their delivery, DEVs can be
engineered for a targeted delivery of their content and can easily reach the proper location on secondary
lymphoid organs compared to the chemokine-dependent migration of DCs [121]. Besides, DCs are
susceptible to immunosuppression exerted by checkpoint signaling or immunosuppressive immune
cells such as Tregs and MDSCs, whereas DEVs are not. Moreover, DEVs possess 10–100 times more
pMHC complexes per surface than DCs [127] and are enriched in NK cell activation ligands [41].
Nonetheless, no DEV-based therapy has been approved to date whilst two DC-based vaccines have
received marketing authorization: Sipuleucel-T (Provenge®), approved by the US Food and Drug
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Administration in 2010; and APCEDEN®, which received authorization by the Indian Central Drugs
Standard Control Organization in 2017. Still, these two DC-based vaccines show limited clinical
benefit [128].
In this section, we will focus on the use of DEVs as therapeutic agents in the context of cancer.
Importantly, we differentiate between vaccination approaches, when EVs are loaded with tumor
antigens in order to elicit (tumor) antigen-specific immune responses, or immunotherapies if they
are not loaded with tumor antigens or their therapeutic effects are based on immunomodulation
independently on whether they improve a later antitumoral antigen-specific immune response.
3.1. DEV-Based Vaccines
Several sources of EVs have been used as potential tumor vaccine candidates. Importantly,
TDEVs have raised a great interest because they are a primary source of tumor antigens that are
potentially preloaded with peptides representative of the tumor mutanome, and they are as well
able to stimulate antitumor DC responses [129]. Also, alternative sources of EVs, e.g., other myeloid
cell types, have been explored [85]. However, DEVs are the most interesting EVs to activate specific
immune responses because: (1) they are antigen-presenting platforms due to the fact that they contain
functional molecules that have a major role in the IS such as MHC-I and-II or CD1 loaded with tumor
peptides as well as co-stimulatory molecules (CD80, CD86) and molecules that enhance cell adhesion
(ICAM-1) ([37,39,130,131] reviewed in [132]); and (2) because the activation state of their cellular source
can be manipulated so that they are devoid of potentially immunosuppressive molecules that may be
present in TDEVs [88]. The induction of antigen-specific responses by DEVs has been demonstrated by
the activation of tumor-specific CD4+ and CD8+ T cells via engagement of their TCR and is superior
to the induction of T cell responses by TDEVs [133,134]. This mechanism, rather than relying on
direct activation of T cells by the DEV-loaded pMHC complexes, is dependent on the transfer of
these complexes to different host DC subsets, increasing the number of DCs carrying tumor pMHC
complexes and acting as an amplifier of the adaptive response [44,45,53]. Moreover, EVs also carry
cytokines [135] and, although this may help to tailor the T cell response, it may not have a major
role in DEVs as the pMHC recipient DCs were shown to be already mature and activated (CD80+ or
CD86+) [45]. Other antitumor mechanisms of DEVs include the activation of NK cells, which, although
not antigen-specific, may mediate directly or indirectly the enhancement of T cell-specific responses by
these or other cellular subsets as it has been shown for some adjuvanted vaccines [136].
3.1.1. DEVs as Tumor Vaccines
Due to the feasibility of large production of DCs for DEVs generation, most studies that
explored the use of DEVs in antitumor settings in ex vivo, in vitro and in vivo have used murine
bone-marrow-derived DCs (BMDCs) as a source for DEVs production. These DEVs have been loaded
with different TAAs to mount specific T cell responses against tumors (Figure 2A). These models
include for example the loading of α-fetoprotein in HCC models [137,138] or chaperone-rich lysates
from the GL261 glioma cell line in glioma models [139]. In these cases, antigen-loaded DEVs were
able to increase overall survival and reduce tumor growth. These effects were accompanied by a
potent activation of both CD4+ and CD8+ T cells responses as measured by IFNγ and IL-2 production,
their infiltration in the tumor, and a reshaping of the immune tumor microenvironment that included
reduction of Treg numbers and less IL-10 and TGF-β production. Importantly, two models of DEV
loading with whole ovalbumin (OVA) protein have shown that whole-protein-loaded DEVs are able to
induce both humoral and cellular immune responses against B16-OVA tumors [66,140]. Indeed, one of
these studies demonstrated increased antitumor efficacy of DEVs loaded with whole OVA protein
compared to DEVs loaded with the MHC-I-restricted OVA257–264 peptide [66].
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Evidence has pointed out that the use of activated DC as producers of DEVs increases the efficacy
of DEVs when used as cancer vaccines [140]. Owing to this, several studies have explored the use of
DEVs coming from DCs stimulated with TLR ligands. For instance, polyinosinic:polycytidylic acid
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(poly(I:C)) treatment of BMDCs increased the antitumor efficacy of DEVs loaded with the human
papillomavirus (HPV) peptide E749–57 both in vitro with TC-1 cells (transformed with E7 protein) and in
a TC-1 model of cervical cancer in vivo [141]. In both settings, poly(I:C) DEVs activated antigen-specific
CD8+ T cells measured by IFNγ production and resulted in a prolonged survival rate in vivo. In order
to decipher which TLR stimulation may be more efficient, a study compared the antitumor efficacy of
DEVs produced from DC stimulated with poly(I:C), lipopolysaccharide (LPS) and CpG (ligands of
TLR3, TLR4 and TLR9 respectively). OVA-loaded DEVs of the TLR3 stimulated group were better
stimulators of OT-I CD8+ and OT-II CD4+ T cells in vivo. In accordance, mice vaccinated with DEVs
from the poly(I:C) group had less tumor growth and longer survival in an in vivo B16-F10 tumor
model, correlating with more robust activation of tumor-specific CD8+ T cells and recruitment NK and
NKT cells [142].
Few ex vivo studies have used human DCs as a source of DEVs. Still, a study used DEVs
produced by human cord-blood-derived DCs and checked their antitumoral capacities. Contrary to
loading DEVs with tumor peptides, total tumor RNA from a human gastric adenocarcinoma
cell line (BGC823) was loaded into DEVs. These RNA-loaded DEVs were superior in inducing
tumor-specific cytotoxic T lymphocytes (CTL) proliferation compared to tumor-lysate-loaded DEVs
ex vivo. Importantly, this study provided an alternate to moDCs as a source for large production of
human DEVs for antitumor vaccination approaches [143].
3.1.2. DEVs as Vaccines for Oncogenic Pathogens
In all these cases, DEVs are used as therapeutic rather than prophylactic vaccines.
Indeed, the prophylactic use of DEVs against cancer is largely unexplored because intervention
is usually used when the disease appears. However, many pathogens have been described to induce
carcinogenesis by direct or indirect mechanisms. These pathogens include viruses (including HPV,
hepatitis B virus (HBV), hepatitis C virus (HCV), human T lymphotropic virus (HTLV) or human
immunodeficiency virus (HIV)-1) and bacteria (Helicobacter pylori) [144]. Approximately 2.2 million
cases of cancer attributable to these infections were diagnosed in 2018 [144]. Other pathogens described
to be associated with human cancer include parasitic diseases such protozoa (Plasmodium falciparum),
and trematodes (Schistosoma haematobium) [145]. Hence, implementation of prophylactic vaccines
that target oncopathogens constitute a potential health benefit. For example, implementation of HPV
vaccination programs has successfully lowered the burden of cervical cancer [146]. However, except for
HPV and HBV, effective vaccines against oncogenic pathogens are lacking.
EVs, in general, have been explored as a novel vaccine platform for infectious diseases to a
lower extent than cancer vaccines, and no clinical trials have been performed to date. In some
cases, EVs have shown increased efficacy than traditional vaccine formulations against pathogens.
Targeting of pathogen proteins to EVs endowed efficient antigen-specific cellular [147] and humoral
immune responses [148] (Figure 2B). Despite the great potential of the EV-based vaccine platforms, a
limited number of studies have been performed using oncogenic pathogens as therapeutic targets.
However, the versatility of these platforms and their similarities with other efficacious and related
vesicle-based platforms such as bacterial outer membrane vesicles [149] make EVs a promising vaccine
platform for targeting oncogenic pathogens.
DEVs have also been explored to generate protection against toxoplasmosis [71,150]. Alternatively,
the immunostimulatory capacities of DEVs have been explored as vaccine adjuvants or adjuvant
carriers. DEVs are able to carry TLR ligands that can stimulate bystander DCs, ultimately inducing
IFNγ production and NK cell activation [151]. Indeed, TLR3 and TLR9 ligands have combined to
DEVs and have been shown to be superior inducers of antigen-specific CD8+ T cell responses [152].
Also, DEVs derived from an LPS-stimulated monocyte cell line administered subcutaneously were
able to potentiate the cellular immune response to the surface antigen of the HBV (HBsAg) when
compared to HBsAg formulated without these vesicles, thereby preventing infection by the oncogenic
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HBV [153]. Lastly, other cellular EVs sources have been explored and described to elicit antigen-specific
antipathogen responses such as T cells [154,155] or infected cells [156–159].
3.2. DEV-Based Immunotherapies
Using human moDCs, Tkach et al. described that DEVs stimulated CD4+ T cell ex vivo.
Activation was biased towards generating a Th1-type response when using small DEVs; and towards
Th2 when using large DEVs from immature cells. Both DEVs sizes induced Th1 cytokines when DCs
were matured with IFNγ [50]. As DCs were not loaded with a specific antigen and a pool of CD4+ T
cells, these results provide an example of DEVs modulating T cell activation. After the observation in a
phase I clinical trial (discussed later) that DEVs pulsed with tumor peptides were unable to mount a T
cell-specific response but induced NK cell activation, another study explored the role of DEV-mediated
NK cell activation as we mentioned in a previous section. Using murine BMDC DEVs administered
intradermally to mice, they observed NK cell proliferation and activation that was mediated by IL-15Rα
and NKG2D ligands present in DEVs (Figure 2C). Also, DEVs derived from human moDCs induced
NK cell activation was dependent on NKG2D ligands [41]. Besides, Munich and colleagues used
murine BMDC DEVs loaded with TNF, FasL and TRAIL describing that these vesicles had the ability to
directly kill B16 tumor cells ex vivo by promoting apoptosis, and also induced NK cell activation and
their IFNγ production [73]. As previously discussed, loading TLR ligands to DEVs, NK cell activation
and bystander DC activation can be achieved [151]. Further exploring the antitumor therapeutic effects
of innate cell activation, Gehrmann U. et al. used murine BMDC DEVs loaded with OVA protein
and the NKT cell activator α-galactosylceramide (αGalCer) in an in vivo B16-OVA tumor model.
Besides inducing T and B cell-specific responses, DEVs loaded with αGalCer were able to induce
a strong innate response based on NKT and γδ T cell activation that resulted in tumor CD8+ T cell
infiltration, reduced tumor growth, and increased survival [160]. DEVs have also been used for direct
drug delivery. DEVs from an immature DC cell line loaded with doxorubicin selectively targeted cells
expressing αv integrin via exosomal loading of the exosomal membrane protein lysosome-associated
membrane protein 2 (LAMP2b) fused to the corresponding integrin-specific peptide iRGD. This allowed
for efficient targeting of breast cancer cells in vitro, tumor targeting in vivo, and reduced tumor growth
after their intravenous injection [161]. Besides, DEVs from DCs exposed to stress conditions as heat
and high concentration of CO2 were able to inhibit a gastric cancer cell line proliferation via apoptosis
induction [162].
3.3. Clinical Trials Using DEVs
To date, four phase I and one phase II clinical trials have been performed using DEVs as
immunotherapeutic agents (summarized in Table 1). Two phase I trials pioneered the use of DEVs
in 2005. Morse MA. et al. used moDC-derived EVs loaded with both MHC-I and -II melanoma
antigen gene (MAGE) peptides directly in isolated DEVs, or indirectly loading cultured autologous
moDCs. An MHC-I-restricted cytomegalovirus (CMV) peptide and an MHC-II-restricted tetanus
toxoid-derived peptide were also loaded in the DEVs. DEVs were injected once per week along 4 weeks
to 9 patients that completed therapy. Delayed-type hypersensitivity (DTH) responses were detected
in 3 subjects and robust CMV responses were detected in 3 individuals, whereas no MAGE T cell
responses were observed. Increase of Tregs and partial enhancement of NK cell functions were observed
in some individuals [163]. In the other pioneering clinical trial, Escudier B. et al. administered DEVs
produced by moDCs on 15 metastatic melanoma patients. Here, DEVs were used as a vaccine platform
as they were loaded with MAGE3 MHC-II and MCH-I peptides (MAGE3168–176 and MAGE3247–258
respectively) and administered four times, once per week. Specific CTL responses in peripheral blood
were not induced or clonally expanded, and only tumor infiltration of activated T cells was described
for a partial response case. On the contrary, NK cell effector functions were shown to be increased [164].
As NK cell functions were partly activated in both studies and, as previously discussed, NK cell
activation and proliferation could be induced by DEVs via DEV-loaded NKG2D and NKp30 ligands,
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and IL-15Rα [41,74]; Viaud S. et al. further explored whether the NK cell activation could account
for the observed clinical effects despite the lack of a T cell response in the clinical study performed
by Escudier B. et al. They described that NK cell numbers were increased in peripheral blood and
NKG2D expression levels were restored both on T and NK cells, enhancing the NKG2D-dependent
cytotoxicity [41]. Another clinical trial phase I by Dai S. et al. used ascites-derived EVs (AEVs) in
combination with granulocyte macrophage colony-stimulating factor (GM-CSF) to treat 40 patients
with advanced colorectal cancer. These vesicles, similar to DEVs, were enriched not only in MHC-I and
MHC-II, but also in CD80 or ICAM-1, and possessed the carcinoembryonic antigen (CEA) as they were
derived from patient malignant ascites. A DTH response as well as a CEA-specific CTL cell response
was efficiently induced when combining AEVs with GM-CSF [165].
Due to the limited clinical benefit shown by these trials, which used immature DC for DEVs
production, Besse B. et al. conducted a Phase II clinical trial using DEVs derived from IFNγ-matured
DC [121]. In this trial, 22 non-small-cell lung carcinoma (NSCLC) patients were administered 4
times with these DEVs loaded with tumor peptides as a maintenance treatment after chemotherapy.
Although no tumor antigen-specific T cell responses could be detected and the primary endpoint of
the study was not reached (50% progression-free survival), the therapy induced a stabilization of the
progression in 32% of patients and one patient benefited from long-term stabilization. These clinical
effects in the absence of T cell responses were probably due to the observed increase in NK cell
functions. These DEVs contained BAG6, a ligand for NKp30 which is induced by IFNγ DC maturation,
which correlated with greater NKp30-dependent production of TNFα and IFNγ by NK cells [166].
Importantly, although in many cases only partial or minor responses were observed, some patients
exhibited stability of the disease progression. Besides, these clinical trials have proven DEVs to be
well-tolerated and safe, and amenable to be produced in large-scale set ups.
3.4. The Future of DEVs in Vaccination Approaches
The increased efficacy and versatility of EV-based vaccines have made them potential candidates
for rapid development of vaccines against emerging infections [122,167]. For example, EVs targeting
has not only increased immunogenicity of EV-based vaccines as discussed before, but it has also been
shown to improve the humoral responses in adenoviral vector vaccines, including ChAdOx1, one of
the candidates leading the race for a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccine [168]. Interestingly, five registered human clinical trials are exploring the use of EVs as
therapeutics against coronavirus disease 2019 (COVID-19) [169–173]. Besides, EV-based vaccines may
contribute to the new era of mRNA vaccination. The use of mRNA-based vaccines is revolutionizing
the field of rapid development of vaccines that is key for development of vaccines against emerging
pathogens and has shown promising results in personalized cancer vaccines via delivery of mRNAs
encoding neoantigens of each patient [174,175]. One of the most critical steps in mRNA vaccination is
achieving an efficient cytoplasmic delivery to target cells. However, this step still poses challenges that
need to be overcome such a toxicity of formulations of reaching target cells in secondary lymphoid
organs [176]. EVs and DEVs have not been explored yet as possible carriers in mRNA vaccination
although they have previously shown to be excellent platforms for delivery of mRNAs and to efficiently
reach secondary lymphoid organs [177].
In most cases, the rationale behind the use of DEVs as tumor vaccines or vaccines for oncogenic
pathogens relies on the classical definition of vaccines as inductors of antigen-specific immune responses
and adaptive memory. However, the broadening of the concept of vaccination with the appearance of
the first generation of trained immunity-based vaccines [178] opens new horizons in exploiting this
new arm of the immune system as a new source of therapeutic strategies for immunotherapy and
cancer vaccines. Indeed, it needs to be determined to what extent trained immunity is playing a role in
the previous examples of DEVs vaccination (e.g., by indirectly enhancing the antigen-specific adaptive
response) or in the immunotherapeutic interventions that we discussed, most of which are based on
immunomodulatory effects in which trained immunity may have a very important role.
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Table 1. Clinical trials using DEVs performed to date and their main immune and clinical outcomes.
Targeted Tumor
Type Phase of Trial n
1 Treatment Loaded Antigen Immune Effects Clinical Outcome Ref.
NSCLC (stage IIIb








DTH reactivity against MAGE
peptides in 3/9.
MAGE-specific T cell responses
in 1/3.
NK lytic activity in 2/4.
CMV responses.







(stage IIIb and IV) I 15 DEVs from moDC
MAGE3168–176 and
MAGE3247–258
Specific T cell responses in
peripheral blood not detected.
One case of tumor infiltration of
activated T cells.
NK cell number and NKG2D
function recovered in 7/14.
NKG2D expression in CD8+








(stage III or IV) I 40 AEVs + GM-CSF Contain CEA
DTH response as well as a
CEA-specific CTL cell response
Well tolerated.
Stabilization in 1 and
minor response in 1.
[165]
NSCLC (stage IIIb










Tumor antigen-specific T cell










1 In parentheses, number of patients that completed therapy; NSCLC, non-small-cell lung carcinoma; CEA, carcinoembryonic antigen; AEVs, ascites-derived EVs; CMV, cytomegalovirus;
DTH, delayed-type hypersensitivity; moDC, monocytic-derived DC; EBV, Epstein-Barr virus; CTL, cytotoxic T lymphocytes; IFNΥ, interferon-Υ.
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4. Conclusions
Extracellular vesicles constitute one of the most efficient mechanisms for intercellular
communication. In the context of tumor development, EVs are present in the tumor microenvironment
and are secreted by a variety of cell types. On the one side, immune cells produce EVs to fight against
tumor progression and metastasis. As illustrated before, DCs, in particular, can secrete EVs to increase
the T cell response by enhancing antigen presentation by a diversity of mechanisms (Figure 1A).
On the other side, malignant cells produce EVs to escape immune responses and virtually, they can
interact with every type of immune cell. Nonetheless, the complexity of these interactions makes
it difficult sometimes to define a clear role of these vesicles. In fact, there is still some controversy
around the immunosuppressive or immunostimulatory role of TDEVs. As we have mentioned,
TDEVs affect myeloid precursor differentiation towards MDSCs, affecting monocytic and DC function
(Figure 1B). Besides, they can directly modulate NK and T cell proliferation and apoptosis. Nevertheless,
other studies pointed out that TDEVs carry TAAs, enhancing the DC responses against malignant cells.
More in vivo studies will shed some light on the understanding of the complex communication net
that modulate cancer development.
The great ability of DEVs as immune modulators and kick-starters of robust antigen-specific T cell
responses and NK cell responses have allowed the use of DEVs in different immunotherapeutic settings:
both as novel and effective cancer vaccines and cancer immunotherapies (Figure 2). Several in vivo
studies as well as clinical trials support the increased efficacy of the use of DEVs as cancer vaccines
compared to DC-based vaccines. However, the prophylactic use of DEVs as a novel and versatile
vaccine platform against infectious agents, including oncopathogens, is still at its inception. Combining
the use of DEVs and emerging technologies such as mRNA vaccination or the exploitation of trained
immunity mechanisms will push forward the frontier of tumor vaccination approaches.
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